All In Biotech

Drug Trial Radar · NCT07654361

Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

A Randomized, Double-Blind, Placebo-Controlled, Pivotal Phase 3 Study to Evaluate the Long-Term Efficacy and Safety of Multiple Maintenance Doses of Once Daily Oral Aleniglipron for Chronic Weight Management in Adults With Obesity or Overweight and a Weight-Related Comorbidity

Last checked: Nov 20, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Title says "pivotal". Randomized with 3,600 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

3,600

Planned (sponsor's estimate)

Start

Jul 13, 2026

Primary completion

Sep 2028

Study completion Nov 2028

Sponsor

Sponsor type
Industry
First posted
Jun 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 79 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study GSBR-1290-12 is a Phase 3 pivotal, multicenter, global, randomized, placebo-controlled, double-blind study to investigate the long-term efficacy, safety, and tolerability of 3 maintenance doses of aleniglipron once daily (QD) compared with placebo, when used in combination with a reduced-calorie diet and increased physical activity. All participants will be randomized to at least 76 weeks of treatment to evaluate the effects on long term body weight changes, tolerability, and safety. In addition, the study will compare the effects between aleniglipron and placebo on blood pressure (BP), lipid parameters, patient-reported outcomes.

Conditions

  • Obesity
  • Overweight
  • Chronic Weight Management

Interventions

  • AleniglipronDrug

    Drug: aleniglipron administered orally Drug

  • PlaceboDrug

    Drug: placebo administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change in body weight from BaselineTime frame: Baseline and Week 76

Locations

71 sites in 1 country. Site status is shown where the registry gives one.

  • ACCOMPLISH-1 Research Site

    Birmingham, Alabama · Not yet recruiting

  • ACCOMPLISH-1 Research Site

    Birmingham, Alabama · Not yet recruiting

  • ACCOMPLISH-1 Research Site

    Phoenix, Arizona · Not yet recruiting

  • ACCOMPLISH-1 Research Site

    Sun City West, Arizona · Not yet recruiting

  • ACCOMPLISH-1 Research Site

    Tucson, Arizona · Not yet recruiting

  • ACCOMPLISH-1 Research Site

    Escondido, California · Not yet recruiting

  • ACCOMPLISH-1 Research Site

    Gardena, California · Not yet recruiting

  • ACCOMPLISH-1 Research Site

    La Jolla, California · Not yet recruiting

  • ACCOMPLISH-1 Research Site

    Modesto, California · Not yet recruiting

  • ACCOMPLISH-1 Research Site

    Rolling Hills Estates, California · Not yet recruiting

  • ACCOMPLISH-1 Research Site

    San Diego, California · Not yet recruiting

  • ACCOMPLISH-1 Research Site

    Clearwater, Florida · Recruiting

  • ACCOMPLISH-1 Research Site

    Leesburg, Florida · Not yet recruiting

  • ACCOMPLISH-1 Research Site

    Miami, Florida · Not yet recruiting

  • ACCOMPLISH-1 Research Site

    Ocala, Florida · Not yet recruiting

  • ACCOMPLISH-1 Research Site

    Ocoee, Florida · Not yet recruiting

  • ACCOMPLISH-1 Research Site

    Pembroke, Florida · Not yet recruiting

  • ACCOMPLISH-1 Research Site

    Tampa, Florida · Not yet recruiting

  • ACCOMPLISH-1 Research Site

    Buford, Georgia · Not yet recruiting

  • ACCOMPLISH-1 Research Site

    Columbus, Georgia · Not yet recruiting

  • ACCOMPLISH-1 Research Site

    Lawrenceville, Georgia · Not yet recruiting

  • ACCOMPLISH-1 Research Site

    Union City, Georgia · Not yet recruiting

  • ACCOMPLISH-1 Research Site

    Woodstock, Georgia · Not yet recruiting

  • ACCOMPLISH-1 Research Site

    Honolulu, Hawaii · Recruiting

  • ACCOMPLISH-1 Research Site

    Meridian, Idaho · Not yet recruiting

  • ACCOMPLISH-1 Research Site

    Rexburg, Idaho · Not yet recruiting

  • ACCOMPLISH-1 Research Site

    Chicago, Illinois · Not yet recruiting

  • ACCOMPLISH-1 Research Site

    Iowa City, Iowa · Not yet recruiting

  • ACCOMPLISH-1 Research Site

    Wichita, Kansas · Not yet recruiting

  • ACCOMPLISH-1 Research Site

    Louisville, Kentucky · Not yet recruiting

  • ACCOMPLISH-1 Research Site

    Baton Rouge, Louisiana · Not yet recruiting

  • ACCOMPLISH-1 Research Site

    Silver Spring, Maryland · Recruiting

  • ACCOMPLISH-1 Research Site

    Methuen, Massachusetts · Not yet recruiting

  • ACCOMPLISH-1 Research Site

    Needham, Massachusetts · Not yet recruiting

  • ACCOMPLISH-1 Research Site

    Ann Arbor, Michigan · Not yet recruiting

  • ACCOMPLISH-1 Research Site

    Mankato, Minnesota · Recruiting

  • ACCOMPLISH-1 Research Site

    Richfield, Minnesota · Recruiting

  • ACCOMPLISH-1 Research Site

    Gulfport, Mississippi · Not yet recruiting

  • ACCOMPLISH-1 Research Site

    Ridgeland, Mississippi · Not yet recruiting

  • ACCOMPLISH-1 Research Site

    Chesterfield, Missouri · Not yet recruiting

Showing 40 of 71 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.